---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-001698"
form_type: "8-K"
ticker: "CELC"
cik: "0001603454"
company_name: "Celcuity Inc."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:51:52.964205+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.72
calibrated_materiality_score: 0.72
confidence: "high"
source: SEC EDGAR
---

# Celcuity posts Q4 net loss $36.7M, cash $235M, key trial data anticipated in 2025

## Summary
- Q4 net loss $36.7M ($0.85/share) vs $18.8M ($0.65/share) in Q4 2023; full year net loss $111.8M ($2.83/share).
- Cash, cash equivalents and short-term investments of $235.1M at Dec 31, 2024, expected to fund operations through 2026.
- PIK3CA wild-type cohort of VIKTORIA-1 Phase 3 topline data expected Q2 2025; mutant cohort data in Q4 2025.
- VIKTORIA-2 Phase 3 first patient enrollment on track for Q2 2025; Phase 1b/2 mCRPC data expected late Q2 2025.
- R&D expenses increased to $33.5M in Q4 from $18.1M, driven by ongoing and new clinical trials.

## SEC filing metadata
- accession: 0001641172-25-001698
- form_type: 8-K
- ticker: CELC
- cik: 0001603454
- company_name: Celcuity Inc.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.72
- calibrated_materiality_score: 0.72
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1603454/000164117225001698/0001641172-25-001698-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1603454/000164117225001698/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-001698
- JSON: https://secwatch.observer/filing/0001641172-25-001698.json
- Plain text: https://secwatch.observer/filing/0001641172-25-001698.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.